Investing
2seventy bio to lay off 40% of workforce
© Reuters.
(Reuters) – 2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm’s cancer cell therapy Abecma.
The company will save about $130 million in 2024-25 as it eliminates 176 roles.
2seventy bio said it expects a decline in Abecma sales in the third quarter and U.S. revenue for the therapy in 2023 could be lower than the $470-$570 million range it previously projected.
The company added that CEO Nick Leschly will step down and transition to the role of chairman.
Read the full article here
-
Passive Income7 days ago
How to Create a Routine That Balances Rest and Business Success
-
Investing7 days ago
This All-Access Pass to Learning Is Now $20 for Black Friday
-
Side Hustles4 days ago
A Macy’s Employee Made Accounting Errors Worth $132 Million
-
Investing4 days ago
Factbox-How Trump can overhaul US financial regulators when he takes office By Reuters
-
Passive Income4 days ago
5 Ways AI Can Accelerate Your Entrepreneurial Journey
-
Side Hustles7 days ago
Gift the Power of Language Learning with This Limited-Time Price on Babbel
-
Side Hustles2 days ago
Closing Your Business? Do It Before the New Year to Save Money
-
Side Hustles6 days ago
I’ve Spent 20 Years Studying Focus. Here’s How I Use AI to Multiply My Time and Save 21 Weeks of Work a Year